Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant

In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant

Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.

PFENegative Net Change MRKPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Sundeep Ganoria

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

NVAXNegative Net Change ARCTPositive Net Change EBSNegative Net Change AXSMNegative Net Change

Zacks Equity Research

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

JNJNegative Net Change MRKPositive Net Change MRNANegative Net Change CRBUNegative Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

NVONegative Net Change MRKPositive Net Change MRNANegative Net Change ACADPositive Net Change